Tarceva Pancreatic Cancer sNDA Planned For 1H05; Avastin Combo To Follow
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
FDA Priority Review Status Refusals Show Need For Clinical Outcomes Data
Sponsors who plan to seek priority review status need to show a superior effect on clinical outcomes, an examination of priority review requests rejected by FDA suggests
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011